How will labs adjust to an environment with multiple viruses hunting for human hosts?

Experts are predicting an increase in influenza cases and a constant presence of SARS-CoV-2 in the shortly approaching influenza season. As SARS-CoV-2 and influenza can share similar clinical symptoms, having access to a diagnostic test that can concurrently detect and differentiate between the viruses will be crucial. It is key for laboratories to prepare for the next influenza season and equip themselves with an accurate, affordable, and scalable test that is highly sensitive and specific for the detection of SARS-CoV-2, influenza A, and influenza B. In this webinar, our speakers will provide an introduction into the epidemiology of SARS-CoV-2, influenza A, and influenza B and explain why it is important to detect and differentiate all three viruses in a single test. We will introduce the workflow and performance of Thermo Fisher Scientific’s Emergency Use Authorized TaqPath COVID-19, Flu A, Flu B Combo Kit, a multiplex PCR test that can detect and differentiate between SARS-CoV-2, influenza A, and influenza B. The TaqPath COVID-19, Flu A, Flu B Combo Kit has a sample-to-results turnaround time of approximately 3 hours and supports testing of up to 94 samples in parallel.

Learning Objectives:

  • Explain the importance of simultaneous testing of SARS-CoV-2 and other respiratory viruses, especially during flu season
  • Assess the approved workflow of an Emergency Use Authorized molecular diagnostic test for COVID-19 and influenza
  • Evaluate performance data of the TaqPath COVID-19, Flu A, Flu B Combo Kit

(*Indicates a mandatory field)